PARC: a phase I/II study evaluating the safety and activity of pegylated recombinant human arginase BCT-100 in relapsed/refractory cancers of children and young adults

PARC: a phase I/II study evaluating the safety and activity of pegylated recombinant human arginase BCT-100 in relapsed/refractory cancers of children and young adults

BackgroundThe survival for many children with relapsed/refractory cancers remains poor despite advances in therapies. Arginine metabolism plays a key role in the pathophysiology of a number of pediatric cancers. We report the first in child study of a recombinant human arginase, BCT-100, in children...

Full description

Bibliographic Details
Main Authors: Nicola Fenwick, Rebekah Weston, Keith Wheatley, Jodie Hodgson, Lynley Marshall, Martin Elliott, Guy Makin, Antony Ng, Bernadette Brennan, Stephen Lowis, Jenny Adamski, John Paul Kilday, Rachel Cox, Mike Gattens, Andrew Moore, Toby Trahair, Milind Ronghe, Martin Campbell, Helen Campbell, Molly W. Williams, Maria Kirby, Natasha Van Eijkelenburg, Jennifer Keely, Ugo Scarpa, Victoria Stavrou, Livingstone Fultang, Sarah Booth, Paul Cheng, Carmela De Santo, Francis Mussai
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Oncology
Subjects:
arginase
arginine
pediatric
cancer
relapse
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1296576/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1296576/full

Similar Items